October 12, 2010

FDA Warning Letter to Maxam Nutraceutics/Maxam Laboratories

On October 12, 2010, the U.S. Food and Drug Administration (FDA) sent a warning letter to Maxam Nutraceutics/Maxam Laboratories for marketing non-prescription “chelation” products as treatments for a range of disorders including autism. The FDA warning to the public noted that the companies’ claims of health benefits for specific conditions have not been proven. No chelation agents have been approved for any use without a prescription. The products have been marketed as “dietary supplements” in a variety of dosages and forms, including suppositories, capsules, liquid drops, sprays and clay baths.